Experiments were conducted to determine whether a potent, reversible calpain inhibitor could re duce the cortical ischemic brain damage associated with focal ischemia in the rat. AK275 (Z-Leu-Abu-CONH CH 2 CH 3 ), the active isomer of the diastereomeric mix ture, CX275, was employed in conjunction with a novel method of perfusing drug directly onto the infarcted cor tical surface. This protocol reduced or eliminated numer ous, nonspecific pharmacokinetic, hemodynamic, and other potentially confounding variables that might com plicate interpretation of any drug effect. Focal ischemia was induced using a variation of the middle cerebral ar-
Ischemic episodes in the brain initiate a time related series of extracellular and intraneuronal events that lead to delayed degeneration of vulner able neurons (Zivin and Choi, 1991) . With global ischemia (e. g. , cardiac arrest, drowning), substan tial neuronal death can take several days (Ginsberg and Busto, 1989) , whereas with focal ischemia (e. g. , stroke), significant cell death typically occurs within hours (Selman et aI. , 1990; Buchan et aI. , 1992) . This delayed cell death in response to isch emia is believed to provide a "therapeutic window tery occlusion method. These studies demonstrated a re liable and robust neuroprotective effect of AK275 over the concentration range of 10 to 200 fLM (perfused supra cortically at 4 fLl/h for 21 h). Moreover, a 75% reduction in infarct volume was observed when initiation of drug treatment was delayed for 3 h postocclusion. Our data further support an important role of calpain in ischemia induced neuropathology and suggest that calpain inhibi tors may provide a unique and potentially powerful means of treating stroke and other ischemic brain inci dents. Key Words: Calpain-Drug delivery-Ischemia Neurodegeneration-Stroke-Therapy-Calcium. of opportunity" for pharmaceutical intervention. Research has therefore focused on identifying key events in the ischemic neurodegenerative cascade, with the hope that neuronal damage can be dramat ically reduced by pharmaceutical intervention. One event widely implicated in ischemic brain damage is abnormally high concentrations of intracellular cal cium (Siesjo and Bengtsson, 1989; Zivin and Choi, 1991) . Elevated calcium levels mediate a cascade of events including activation of numerous calcium dependent enzymes that, if left uncontrolled, can impart serious structural damage to neurons (Siesjo and Bengtsson, 1989; Zivin and Choi, 1991) .
One such class of calcium-dependent proteases is the calpains. Calpains are cytosolic neutral thiol proteases that degrade numerous cytoskeletal pro teins, as well as activate and/or degrade certain in tracellular signal transducers (including protein ki nases C and A, phospholipases, and protein phos phatases) (Mellgren and Murachi, 1990) . Recent research has suggested that, given the diversity and type of intracellular reactions induced, calpain ac-tivation may represent a final common pathway in many types of brain damage (Siman et aI., 1985 (Siman et aI., , 1989 Seubert et aI., 1988 Seubert et aI., , 1989 Seubert et aI., , 1990 Siman and Noszek, 1988) . Therefore, selective inhibition of calpain may be an attractive therapeutic strategy in the treatment of neurodegenerative diseases (Bar tus, 1990) .
A potential therapeutic role for calpain inhibitors is buttressed by the fact that calpain normally exists in a quiescent, inactive state and becomes pro teolytically active when high levels of intracellular calcium are achieved. Since intracellular calcium levels are tightly regulated, the concentrations re quired to activate calpain are rarely observed in normal adult neurons. However, high calcium lev els are clearly associated with ischemia-induced neuropathology (Siesjo and Bengtsson, 1989 ). Thus, one might predict that calpain inhibitors may not only block this ischemia-related pathogenic cas cade but have limited liability regarding interfer ence with normal neuronal function.
Recent work has begun to implicate calpain pro teolysis as an important component of the neurode generation following cerebral ischemia. For exam ple, in both global (Seubert et aI., 1989) and focal (Bartus et aI., 1994, submitted) ischemia, calpain induced breakdown products of spectrin (a prev alent substrate for calpain found in many cells, including neurons) are observed early in the neuro degenerative cascade, in advance of major cytopa thology. Additionally, hippocampal slices main tained in vitro can be partially protected against the anoxia-induced loss of excitatory postsynaptic po tential (EPSP) if certain calpain inhibitors are per fused for 1 to 4 h prior to deoxygenating the slice medium temporarily (Arai et aI., 1990) . To date, two in vivo studies have been published with calpain inhibitors. In the first, it was shown that the ischemia-induced degradation of one calpain sub strate (MAP2) could be blocked by pretreatment with E-64c, an irreversible calpain inhibitor, al though degradation of another calpain substrate (myelin-associated glycoprotein) was not prevented (Inuzuka et aI., 1990) . In the second study, a high dose of leupeptin (a nonspecific inhibitor of calpain, with equally potent inhibitory effects against certain serine and lysosomal thiol proteases) (Rich, 1986; Mehdi, 1991) was continuously infused into the lat eral ventricle of gerbils for 3 days prior to transient global ischemia. This preischemic treatment regi men protected the hippocampus from both the neu ral degeneration and the spectrin proteolysis asso ciated with transient global ischemia, (Lee et aI., 1991) . While these studies provide encouraging cir cumstantial support for a role of cal pain in cerebral J Cereb Blood Flow Metab, Vol. 14, No.4, 1994 ischemia, more convincing evidence is req,uired to establish that calpain inhibitors might be clinically effective therapies to limit the brain damage asso ciated with stroke and other ischemic incidents.
The present study was designed to provide more convincing and unambiguous evidence for the ther apeutic utility of calpain inhibitors per se, including clinically relevant tests of postocclusion interven tion. At the same time, attempts were made to ad dress numerous issues recently cited in the litera ture (e.g., choice of model and species, size of groups, inadequate evaluation of drug effect) as lim iting the clinically predictive value of past data from animal models of stroke (e.g., Ginsberg and Busto, 1989; Pulsinelli et aI., 1989) . Toward these ends we have undertaken a comprehensive examination of the dose-response effects of a prototypic cal pain inhibitor using modifications of established models of stroke and a novel method for direct, cortical superfusion of the drug. Additionally, we studied the effects of varying the time between initiation of the stroke and initiation of the drug administration. For all drug studies, AK275, the active L, L isomer of Z-Leu-Abu-CONH-CH2CH3 was used. The dia stereomeric mixture of this compound (also known as CX275) was originally synthesized by Li et al. (1993) , while the stereospecific synthesis of this compound was developed at Alkermes, Inc. (Har beson et aI., submitted).
AK275 is one of a series of proprietary dipeptidyl a-keto amides currently under development by Alkermes, Inc., as therapeutics for stroke and other forms of neurodegeneration. These compounds are characterized as relatively potent and selective in hibitors of calpain (e.g., the Kj for AK275 against calpain I = 77 nM; this represents orders of mag nitude greater potency for calpain than for serine proteases or many other thiol proteases) (Li et aI., 1993; Harbeson et aI., submitted) . Moreover, these compounds have been shown to penetrate cell membranes, have a relatively long half-life (i.e., >60 min) in static plasma, liver homogenate, and CSF, and offer significant protection of hippocam pal slices against anoxia-induced loss of normal neurophysiologic function (Bartus, 1991; Ton et aI., 1991 Ton et aI., , 1993 . AK275 was selected for these studies because among the inhibitors thus far synthesized, it possessed one of the more favorable profiles of in vitro potency, efficacy, selectivity, membrane per meance, and solubility.
MATERIALS AND METHODS

Subjects and vivarium conditions
Male Sprague-Dawley rats (N = 210; 250-350 g; Taconic, Germantown, NY, U.S.A.) were used for these studies. The animals were acclimated to our vivarium for 5-14 days prior to surgery and housed in polycarbonate cages (40 x 20 x 20 cm) filled with hardwood bedding (Beta-Chips; Northeastern Products, Warrensbury, NY, U.S.A.). Water and food (Purina Laboratory Rat Chow No. 5001; Purina Mills, St. Louis, MO, U.S.A.) were available ad libitum throughout the experiment. The vi varium was maintained at 72 ± 2°F, with a relative hu midity of 40 ± 4% on a 12:12-h light/dark schedule.
Focal model of cerebral ischemia
A variation of the craniotomy middle cerebral artery occlusion (MCA-O) method, originally developed by Tamura et al. (1981) and refined by Chen et al. (1986) , was employed in these studies. In this method the left MCA is permanently ligated, while the common carotid arteries are bilaterally and temporarily occluded. All rats were anesthetized with a 4 mllkg mixture of ketamine (25 mg/ ml), xylazine (1.3 mg/ml), and acepromazine (0.33 mg/ml) after premedication with atropine methylbromide (0.1 mg/ kg, i.p.). The common carotid arteries (CCA) were dis sected free of the vagus nerve and surrounding fascia through a ventral midline cervical incision. To locate the left MCA, a I.O-cm vertical incision was made in the left temporal region midway between the lateral canthus of the eye and the external auditory canal. The temporalis muscle was bisected and the superior attachments were retracted in both rostral and caudal directions. The bifur cation (of the frontal and parietal branches) of the MCA was visualized through a craniotomy made 3-4 mm in front of the junction of the zygomatic arch and the squamosal bone. The parietal branch was occluded up to 2.0 mm distal from the bifurcation using a single 10-0 suture (Ethicon Inc., Somerville, NJ, U.S.A.), taking care to include in the occlusion any major branches that may bifurcate from the parietal branch within 2.0 mm of the frontallparietal bifurcation. Immediately following permanent ligation of the parietal branch of the left MCA, the CCAs were temporarily occluded bilaterally, using atraumatic aneurysm clips (Roboz Surgical Instruments, Rockville, MD, U.S.A.). The temporalis muscle was then sutured with a single 3-0 nylon stitch and the skin closed with three surgical wound clips. One hour later, the an eurysm clips were removed from the CCAs (allowing spontaneous reperfusion) and the wound was closed.
Body temperature was regularly monitored (via rectal probe), recorded, and maintained (normothermic) throughout and following the MCA-O procedure by plac ing the animals on heating pads. If an animal's tempera ture fell below 36°C or rose above 38°C and could not be quickly corrected, the animal was eliminated from the study. Very little variation (and no consistent group dif ferences) in body temperature were observed in any of the studies described in this paper (see Experiment 3 un der Results and Table I for more detailed information on this point). Moreover, a comparison of body temperature from rats supracortically perfused with vehicle versus a high concentration (200 fLM) of AK275 revealed no dif ferences (vehicle mean = 36.7°C, AK275 mean = 36.69°C; t = 0.04, df = 19, p > 0.10).
Animals were returned to their home cages once their righting reflex was established. All animals were killed at 21 h following MCA-O, as described below. At the time of kilUng, animals given MCA-Os typically did not exhibit unusual psychomotor or other overt behavioral abnor malities unrelated to the general surgical intervention; that is, no behavioral consequences of the brain infarct per se were readily detected,
Supracortical perfusion
To provide the most direct test of the effect of a calpain inhibitor on cerebral ischemia, we developed a novel method of chronically perfusing drug directly into the cor tical surface; we termed this the "supracortical perfusion method" (Fig, I) , Animals were anesthetized with 3% halothane in O 2 and placed in a stereotaxic apparatus, Following a midline sagittal skin incision on the cranium, the left parieto-occipital bone region was exposed and a small burr hole was made on the lambdoid suture 5 mm from the midline, Subsequently, the underlying dura was incised and raised and polyethylene (PE-IO) tubing in serted 3,0 mm along the dorsal surface of the occipital cortex. The tubing was secured in place using Gelfoam (Upjohn Pharmaceuticals, Kalamazoo, MI, U.S.A.) and cyanoacrylate-based glue. This tubing was connected via PE-50 tubing to an osmotic pump (model 200lD; Alza Corp., Palo Alto, CA, U.S.A.), which was implanted sub cutaneously (below the scapula region) at various time points, pre-or post-MCA-O surgery. Surgical wound clips were used to close the skin.
Preliminary studies were conducted to establish (a) the
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FIG.1. Supracortical perfUSion. Schematic representation of the "supracortical perfusion" system used to administer drugs in these studies. This self-contained system permitted continuous, controlled perfusion of drug directly onto the infarcted cortex in freely moving animals. The diagram illus trates the dorsal view of the rat brain as it sits within the skull (the dorsal surface of cranium is not shown, but approximate locations of the bregma and lambda sutures are indicated).
The coronal sections noted in the brain (numbered 2 through 6) illustrate the approximate locations of the 2-mm sections harvested from each brain for TTC staining and quantitative image analysis (to determine the volume of infarct under ve hicle and calpain inhibitor conditions).
placement of the PE-lO tubing tip on the surface of the cortex in relation to the area of infarct and (b) the appro priate Alzet osmotic pump flow rates. Pumps were filled with 1% Evans blue dye (in artificial cerebrospinal fluid; aCSF) and implanted into rats, which were subsequently killed at various times. With the dye as a visual aid, the placement and angle of the PE-lO tubing were varied to determine the optimal placement of the tip such that the area of infarcted brain would be covered by the pump's contents. In addition, we observed that supracortical per fusion of vehicle at 8.0 J.d/h caused excessive brain edema after 25 h, especially in MCA-O animals (data not shown).
To rectify this problem, 50% of each of the pumps' outer surface area was coated with paraffin wax to reduce the flow rate to approximately 4.0 fJ.-lIh; subsequently, no de tectable brain edema was noted.
Tissue processing
Twenty-one hours after the induction of focal ischemia, rats were deeply anesthetized with CO 2 and decapitated, and their brains rapidly removed. The posterior portion of the cerebellum was discarded. The remaining brain tissue was chilled in ice-cold saline for 10 min (0-4°C) and placed in a chilled brain matrix (model REM4000C; Ac tivational Systems Inc., Warren, MI, U.S.A.). Seven 2.0mm coronal sections were cut in an anterior direction from the cerebullum, immersed in lO ml of a 2.0% solu tion of 2,3,5-triphenyltetrazolium chloride (TTC; Sigma Chemical Co., St. Louis, MO, U.S.A.), and placed in a 37°C incubator for 30 min (15 min with each surface facing up).
TTC is an established marker for functional mitochon drial oxidative enzymes and produces a visible deep red colored formazan derivative within normal tissue (Sand ritter and Jestadt, 1958; Cole et aI., 1990) . Ischemic tissue has impaired or no mitochondrial activity, and TTC there fore does not stain the tissue. Tissue with reduced mito chondrial activity is stained pink.
After staining, sections were washed twice in lO ml of 0.9% saline, placed in 10 ml of 10% formalin solution, and left at 4°C overnight in a lightproof container. Following two additional washes in 0.9% saline (10 ml), computer digitization of each section and subsequent image analy sis were undertaken.
Tissue section analysis
All digitizing, the subsequent computer imaging and infarct quantitation were performed under blinded (i.e., coded) conditions. Digitized, color images of each caudal and rostral side from each section (total 14 images per brain) were generated using Kodak SV-printer 1.1 soft ware and a Kodak RGB 4000 videocamera. Stored digital images were then enlarged on a color monitor and areas of interest highlighted and analyzed using the software package Image 1.44 (NIH program). The infarcted area (white tissue), as well as the "total damage" (infarcted plus pink-stained tissue), was then computed from these digitized images.
The total and infarct volumes of cortical ischemic tis sue induced by the MCA-O were calculated for each an imal using the equation below, and subsequently group means were determined. The mean volume of infarcted tissue for vehicle-treated animals, across all studies, was 61 mm 3 , whereas the ' vol ume for total damaged tissue was 87 mm 3 •
Statistical analysis
Data collected from the imaging system were down loaded directly onto a spreadsheet (Microsoft Excel) from which analyses were carried out. Due to day-to-day vari ance in the volume of ischemic damage in the vehicle treated animals (df = 39, F = 3.73, p = 0.004), scores from each vehicle and drug-treated animal were trans formed and values are expressed as a percentage of the vehicle mean from each respective study (i.e., individual day). Individual scores could, in theory, vary from 0% to near-infinity, with scores exactly equal to the vehicle mean designated lOO% (of that score). Thus, the data nor malized in this fashion produced a distribution of scores for each group, from which a mean and standard devia tion could be computed and statistical tests performed. The data from each experiment were analyzed statisti cally using either two-tailed t tests, in Experiment I, or an analysis of variance (ANOV A) for multiple groups, in Experiments 2 and 3. Once the ANOV A confirmed that differences between treatments existed, a limited number of comparisons were performed between vehicle control and specific treatment groups, using the Dunnett test of multiple comparisons.
Drug studies
Three separate series of experiments were conducted to determine the effect of the calpain inhibitor, AK275, on infarct size following MCA-O. AK275 was initially dis solved in lOO% dimethyl sulfoxide (DMSO) 
RESULTS
Experiment 1
The results of this study illustrate a substantial reduction in MCA-O-induced ischemic injury with AK275 pretreatment. Drug treatment resulted in a 57% reduction in infarct volume (white unstained, t = 3. 13, df = 27, p < 0.004, two-tailed) and a 50% reduction in volume of total damage (white plus pink, t = 3. 21, df = 27, p < 0.004, two-tailed) versus vehicle-treated controls (Fig. 2) .
Experiment 2
The results of administering different concentra tions of AK275 are shown in Fig. 3 and demonstrate a dose-dependent effect on ischemia-induced cell damage. An overall ANOV A indicated significant differences between vehicle and drug-treated groups for both total damaged tissue [F(6, 90) = 3.52, p < 0.004] and infarcted tissue only [F(6, 90) = 3.66, p < 0.003]. Individual comparisons indicated that neither the 1. 0 nor the 5. 0 IJ-M concentrations of AK275 were different from the vehicle (p > 0. 10) and that the minimal effective concentration of AK275 was 10 IJ-M (Dunnett's q =2. 67, df = 42, p < 0.05). The effect of 200 IJ-M AK275 in this study was similar to that in the first (total damage-50 % reduction, Dunnett's q = 3. 22, df = 41, p < 0.01; infarct volume-47% reduction, t = Dunnett's q = 3.22, df = 41, p < 0.01).
Experiment 3
The results of this study demonstrated that delay ing the administration of AK275 to 1 and 3 h post occlusion reduced the infarct volume by 46 and 75%, respectively (Figs. 4 and 5) . Similar reduc tions were noted when the total damage was calcu- lated (Fig. 6 ). However, with a delay of 4 h between MCA-O and initiation of drug administration, treat ment was ineffective (p > 0.10). Overall ANOV As for the total damaged and infarcted tissue indicated a reliable difference between vehicle-and AK275treated groups from 1-, 3-, and 4-h studies [F(80,3) = 13. 21, p < 0.0001, and F(80,3) = 14. 35, p < 0.0001, respectively]. Individual Dunnett's compar isons between vehicle and drug treatment revealed reliable reductions in ischemic damage for both the 1-and the 3-h delayed treatment conditions for total damage (1 h-q = 3. 10, df = 53, p < 0.01; 3 h-q = 5. 60, df = 59, p < 0.01), as well as infarct vol ume (1 h-q = 3. 15, df = 53, p < 0.01; 3 h-q = 5. 9, df = 59, p < 0.01).
As noted earlier, body temperature was regularly monitored and maintained in all experiments. To help assure that chance variations in temperature did not contribute to the treatment effects reported here, we analyzed the rectal temperature from each group of animals in this study during three key time points within the MCA-O procedure: 2 to 5 min prior to initiating surgery (but while under anesthe sia), at the time the occlusions were performed, and just following reperfusion (i. e. , immediately upon release of the clips occluding the CCAs). These data are shown in Table 1 , illustrating both that little variation in body temperature occurred and that no consistent differences among groups were noted. The latter point was confirmed with a series of ANOV As performed at each of the three time points within the MCA-O procedure, indicating no difference in rectal temperature among the four treatment conditions at the pre surgery time point (F = 1. 00, df = 3, 80, p > 0.10), at the initial occlusion time point (F = 1. 61, df = 3,80, p > 0.10), and at reperfusion (F = 0.13, df = 3,80, p > 0.10). Thus, the differences in infarct volume among treatments noted here certainly cannot be due to chance vari ations in body temperature during the MCA-O pro cedure.
DISCUSSION
The present series of studies demonstrates that a potent calpain inhibitor, AK275, applied directly to FIG. 3 . Experiment 2. The protective effect of AK275 was confirmed and extended using a range of concentrations under the same con ditions as in Experiment 1. Note that no reli able effect was achieved at either 1.0 or 5.0 f1M but that the effects at 10 f1M and higher were significant, with 200 f1M providing the most robust and consistent effect (strikingly similar to that observed in Experiment 1). Bars represent means; vertical lines, one standard deviation. Overall dose response ANOVA: p < 0.003. the surface of ischemic neocortex can dramatically and unequivocally reduce the size of the expected infarct. By employing relatively large numbers of animals per group, testing several doses of drug, and using a predictable and accepted model of stroke, we hoped to eliminate the most serious crit icisms raised against many past studies of therapeu tic strategies for treating stroke (e. g. , see Ginsberg and Busto, 1989; Pulsinelli, 1989) . Moreover, by de veloping and employing a method that permitted us AK275 75% reduction FIG. 4. TTC serial coronal sections. Rostral surfaces from serial, coronal sections (2 mm) taken from three representative rats. The left-hand sections were taken from an animal administered vehicle; the white, infarcted area (visualized via TTC staining) was typical of the damage incurred under control conditions. The center and right-hand sections were from animals administered AK275 and represent 50 and 75% reductions in the volume of damage, relative to control rats. Overall ANOVA: p < 0.0001 . to treat the target brain tissue directly, we at tempted to minimize various hemodynamic, hypo thermic, and other potentially confounding vari ables that have raised interpretative questions re garding the neuroprot e ctive effects observed with certain drugs in past studies, e.g., MK801 (Hay ward et aI., 1993), nimodipine (Greenberg, 1987; Ginsberg et aI., 1991) , and the lazaroids (Hall, per sonal communication, Winter Conference on Brain Research, 1993) . From this perspective, we believe that these data provide compelling evidence that supracortically administered AK275 can protect the brain against focal ischemia by intervening directly in the neurodegenerative cascade. While it cannot be concluded from this study whether the inhibitor completely arrested the pathogenesis (and the pro tective effects therefore would continue to be ob served days or we�ks later), there is little doubt that the specific inhibitor used here produced substan tial, positive effects on the expression of infarct size one day after the occlusion. As such, these data also provide additional circumstantial support for an i mportant role of calpain proteolyses in the neu ropathogenesis of ischemia-induced brain damage. While these studies, alone, do not permit us to conclude that AK275 necessarily produced its ef fects through inhibition of calpain, the fact that it was successfully designed [through structure activity relationships (Li et aI., 1993) ] to be a potent and relatively selective calpain inhibitor is, none theless, highly suggestive. The robust and consis tent protection achieved by AK275 in an estab lished rat focal model (MCA-O) offers the most compelling evidence, to date, that calpain inhibitors may represent a novel and powerful means of treat ing stroke and related brain ischemic incidents. That such robust protection was seen when the drug infusion was delayed for 3 h postocclusion raises confidence that the practical need to achieve suffi ciently rapid clinical intervention may be possible with a cal pain inhibitor. This point becomes partic ularly salient when one considers that, in these studies, once the infusion was initiated, an addi tional period was required for the perfused drug to penetrate the areas that were salvaged. At a perfu sion rate of 4.0 I.d/h, this time is likely measured in hours, and not minutes. One might expect that once AK275 (and related inhibitors currently under de velopment) is formulated for parenteral administra-tion and its transport to brain neurons facilitated by the cerebral vascular system, the window for ther apeutic intervention may be opened for even longer durations. This and related work is the focus of cur rent effort.
